VYGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Voyager Therapeutics Inc (VYGR) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. While the company has shown significant revenue growth, its financial health remains concerning with increasing net losses and declining EPS. Additionally, insider selling and lack of positive trading signals suggest caution. The technical indicators are neutral, and there are no recent news catalysts or strong analyst upgrades to support a buy decision.
The MACD histogram is below 0 and negatively contracting, indicating a lack of bullish momentum. RSI is neutral at 56.811, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are at 3.705 and 4.668, respectively, with the stock currently trading near the pivot level of 4.187.
Revenue increased by 144.28% YoY in Q4 2025, and gross margin remains at 100%.
Net income dropped by 20.47% YoY, EPS declined by 20.34% YoY, and insiders have increased selling activity by 591.56% over the last month. No recent news catalysts or congress trading data available.
In Q4 2025, revenue increased significantly to $15.34M (up 144.28% YoY), but net income dropped to -$27.43M (down 20.47% YoY), and EPS fell to -0.47 (down 20.34% YoY). Gross margin remained at 100%.
Morgan Stanley raised the price target from $25 to $39 but maintained an Equal Weight rating, indicating a neutral stance. The analyst notes potential benefits from the Space Superiority Executive Order but highlights uncertainty around tangible impacts.
